Broker tips: Shire, Next, Cineworld
3rd Nov 2016 10:37
(ShareCast News) - Credit Suisse downgraded retailer Next to 'underperform' from 'neutral' and slashed the price target to 4,600p from 4,950p. The bank said it was becoming increasingly cautious about Next's ability to stabilise margins in an environment of rising opex and input costs, and with bran
Read moreShire rallies on Merrill, Citi notes
3rd Nov 2016 09:33
(ShareCast News) - Shire got a boost on Thursday as Bank of America Merrill Lynch added the stock to its 'Europe 1' list with a 'buy' rating and 6,970p price target, saying the shares are too cheap. The bank pointed out that Shire shares have been weak since the third quarter results due to a 3% rev
Read moreShire slips on third-quarter earnings report
1st Nov 2016 12:04
(ShareCast News) - Third-quarter revenues and earnings from Shire were just shy of forecasts, while the drug developer did not raise guidance as some had hoped, due to higher than expected costs from June's acquisition of Baxalta. Costs related to the licensing of its SHP647 drug for ulcerative coli
Read moreSector movers: Macquarie delivers boost for miners
31st Oct 2016 14:32
(ShareCast News) - Media and mining stocks paced gains at the start of the week. Advertising colossus WPP reported that quarterly revenues grew 23.4%, with over 15 percentage points of that growth rate coming from currency translation effects as the pound weakened. Indeed, LFL net sales growth was
Read moreFTSE 100 movers: Shire and Next sold off ahead of results
31st Oct 2016 14:23
(ShareCast News) - The FTSE 100 was traipsing lower on Monday afternoon, led down by an assortment of companies across sectors, notably those that are due to report in the coming few days. Shire, which is scheduled to post its third-quarter results on Tuesday, was bottom of the pile as the drug deve
Read moreSector movers: Tesco leads cyclicals higher, pharma drags
14th Oct 2016 12:54
(ShareCast News) - Cyclicals took over from defensives, with Tesco spearheading gains among food and drug retailers while pharma stocks acted as the main drag. Tesco shares accounted for the lion's share of the gains in that sector after Unilever said issues surrounding the supply of its leading bra
Read moreWednesday broker round-up
12th Oct 2016 14:40
(ShareCast News) - Shire: Goldman Sachs keeps at buy with a target price of 6300p. Page Group: HSBC reiterates hold, 385p target. McCarthy & Stone: UBS keeps at sell with a 150p target. Arrow Global: Macquarie reiterates outperform with a 335p target. Electrocomponents: Citigroup keeps at neutral
Read moreWednesday broker round-up
28th Sep 2016 12:15
(ShareCast News) - Close Brothers Group: Barclays reiterates overweight with a target price of 1500p. Royal Dutch Shell: HSBC keeps at buy, 2050p target. William Hill: Deutsche Bank keeps at buy with a 390p target. The Restaurant Group: Berenberg reiterates hold with a 350p target. Astrazeneca: D
Read moreTuesday broker round-up
27th Sep 2016 13:05
(ShareCast News) - Vodafone: HSBC reiterates buy with a target price of 280p. Melrose: UBS upgrades to buy, 200p target. Marks & Spencer: Deutsche Bank keeps at hold with a 350p target. Shire: Berenberg reiterates buy with a 5800p target. Next: Deutsche Bank keeps at buy with a 5950p target. Llo
Read moreMonday broker round-up
26th Sep 2016 14:17
(ShareCast News) - N Brown: HSBC downgrades to hold with a target price of 205p. Kingfisher: UBS downgrades to neutral, 390p target. Morrison: Credit Suisse keeps at neutral with a 200p target. WPP: Jefferies downgrades to hold with a 1850p target. Wolseley: Exane BNP Paribas keeps at underperfor
Read moreMonday broker round-up
19th Sep 2016 09:52
(ShareCast News) - Lloyds: Jefferies reiterates buy with a target price of 67p. Astrazeneca: UBS reiterates buy, 5480p target. Britvic: JP Morgan keeps at underweight with a 590p target. Unilever: UBS reiterates neutral with a 3380p target. IHG: HSBC starts coverage at reduce with a 2900p target.
Read moreShire gets FDA approval for primary immunodeficiency drug
14th Sep 2016 14:57
(ShareCast News) - The US Food and Drug Administration has granted approval for Shire's Cuvitru drug for the treatment of patients with primary immunodeficiency, which is a group of more than 300 genetic disorders. Shire said it expects to launch the drug in the US in the coming weeks. It was alread
Read moreShire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing
25th Aug 2016 09:14
(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators
Read moreFTSE 100 movers: Housebuilders lead equities higher
23rd Aug 2016 13:58
(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J
Read moreShire launches von Willebrand disease drug in the US
9th Aug 2016 12:31
(ShareCast News) - Shire announced the US launch of Vonvendi on Tuesday, which is the only recombinant treatment for adults living with von Willebrand disease (VWD) - a hereditary bleeding disorder. Vonvendi was approved by the US Food and Drug Administration in December 2015 and is indicated for on
Read more